Clearpoint Neuro Inc

Clearpoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The firm conducts its procedures under direct, intra-procedural magnetic resonance imaging guidance. Its product platform consists of the ClearPoint system and ClearTrace system. The company was founded by Paul A. Bottomley on March 12, 1998 and is headquartered in Solana Beach, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ClearPoint Neuro reports revenue growth, faces margin pressures in 2022

ClearPoint Neuro's financial performance in 2022 showed revenue growth but faced margin pressures and increased operating expenses.
The company's strengths lie in revenue growth projections, successful product launches, and cost-saving initiatives.
Challenges include post-COVID operational disruptions, supply chain concerns, and achieving cash breakeven targets.
Opportunities exist in R&D investments, international expansion, and maintaining an optimistic outlook for future growth.

ClearPoint Neuro reports Q1 growth, targets $50M revenue by 2025

ClearPoint Neuro Inc's Q1 performance reflects steady revenue growth and strategic investments to drive future expansion and innovation.
While facing challenges in certain revenue segments and margin decline, the company's strong growth strategy and focus on key areas present opportunities for sustained success.
With a clear roadmap to achieve revenue targets, expand partnerships, and launch new products, ClearPoint is poised for continued growth and market leadership in the neurosurgery sector.

ClearPoint Neuro reports record revenue and growth strategy focus

ClearPoint Neuro Inc's Q2 2023 earnings call highlighted record revenue, growth pillars, and operational efficiency improvements. Challenges include installation barriers and regulatory expansions, while opportunities lie in neuro-oncology expansion and pharma partnerships. The company aims for cash flow breakeven by 2025 and emphasizes long-term pharma relationships.

ClearPoint Neuro reports improved Q3 performance amidst strategic growth plans

ClearPoint Neuro's Q3 2023 performance showed improvements in operational cash burn and revenue growth in key segments, despite challenges in gross margin and operating expenses.
The company's strategic focus on innovation, patient outcomes, and market expansion presents opportunities for sustained growth and competitiveness in the healthcare sector.
While facing challenges in cost management and market access, ClearPoint Neuro is well-positioned to leverage opportunities in new revenue streams, product launches, and operational enhancements.
Overall, ClearPoint Neuro's commitment to improving patient outcomes, expanding market reach, and driving innovation underscores its potential for future success and growth.

ClearPoint Neuro reports robust Q4 earnings, eyes growth opportunities

ClearPoint Neuro's strong Q4 performance and revenue growth in 2023 position the company well for 2024. Despite challenges with EU MDR certification, ClearPoint is investing in partnerships to overcome regulatory hurdles. Opportunities for growth include new product releases and expanding market presence.

ClearPoint Neuro reports 41% revenue growth in Q1 2024

ClearPoint Neuro's Q1 2024 earnings call showcased robust revenue growth, controlled expenses, and a strategic focus on key growth areas. The company's optimistic outlook for 2024 is supported by strong demand from pharmaceutical partners and expansion initiatives.

ClearPoint Neuro reports record revenue growth and raises full-year guidance

ClearPoint Neuro's Q2 2024 performance reflects robust revenue growth and a solid financial position.
The company's focus on key growth pillars and increased revenue guidance for the year signal a positive outlook for future expansion.
While challenges in cost management and market competition exist, ClearPoint Neuro's strengths and opportunities position it well for sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOLANA BEACH, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2022 first quarter on Wednesday, May 11, 2022, after the market close.

ClearPoint Neuro to Announce First Quarter 2022 Results May 11, 2022

SOLANA BEACH, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today that its management will present at the B. Riley Securities Disruptive Biotech Enabling Technologies Mini Conference on Thursday, April 7, 2022 at 2:30 p.m. Eastern Time.

ClearPoint Neuro to Present at the B. Riley Securities Disruptive Biotech Enabling Technologies Mini Conference

ClearPoint Neuro's (CLPT) CEO Joe Burnett on Q4 2021 Results - Earnings Call Transcript

Company Reports Record Revenues Company Reports Record Revenues

ClearPoint Neuro Reports Fourth Quarter and Full-Year 2021 Results

Company to Hold Earnings Call on March 1, 2022 Company to Hold Earnings Call on March 1, 2022

ClearPoint Neuro Reports Fourth Quarter and Full Year 2021 Preliminary Revenue Results and Guidance for Full Year 2022 Revenue

Even though elective procedures are returning to the pre-pandemic level, the rise of the Omicron variant resurgence may continue to impact the case volume in the upcoming quarters. ClearPoint Neuro is working with 40 biology partners as of Q3'21, and with 100 potential partners in the intracranial and spine segment, this increases the odds of multiple commercialization.

ClearPoint Neuro: Underlying Growth Potential Concealed By COVID

SOLANA BEACH, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today that its management will participate at the H.C. Wainwright BIOCONNECT Virtual Conference. A pre-recorded company presentation will be available on the conference website beginning at 7 a.m. ET / 4 a.m. PT on January 10, 2022.

ClearPoint Neuro to Participate at the H.C. Wainwright BIOCONNECT Virtual Conference

SOLANA BEACH, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates partner Blackrock Neurotech for receiving Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its groundbreaking MoveAgain Brain Computer Interface (BCI) system.

ClearPoint Neuro Congratulates Blackrock Neurotech on Receiving Breakthrough Device Designation from the FDA for the MoveAgain Brain-Computer Interface System

ClearPoint Neuro, Inc. (CLPT) CEO Joseph Burnett on Q3 2021 Results - Earnings Call Transcript

Record Revenue Achieved; Company Reaffirms 2021 Revenue Forecast Record Revenue Achieved; Company Reaffirms 2021 Revenue Forecast

ClearPoint Neuro Reports Third Quarter 2021 Results

SOLANA BEACH, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates partner Neurona Therapeutics on clearance by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application to initiate its first-in-human Phase 1/2 clinical trial evaluating the safety and efficacy of NRTX-1001 in patients with drug-resistant mesial temporal lobe epilepsy (MTLE).

ClearPoint Neuro Congratulates Neurona Therapeutics on IND Clearance for Neural Cell Therapy NRTX-1001 in Chronic Focal Epilepsy Patients

SOLANA BEACH, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, is pleased to announce that Linda M. Liau, MD, PhD, MBA, has been appointed to the Company's Board of Directors effective immediately.

Internationally Renowned Neurosurgeon and Accomplished Researcher Dr. Linda M. Liau Joins ClearPoint Neuro Board of Directors

SOLANA BEACH, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2021 third quarter on Tuesday, November 9, 2021, after the market close.

ClearPoint Neuro to Announce Third Quarter 2021 Results November 9, 2021

ClearPoint provides a complete navigation system that enables neurosurgeons to perform minimally invasive procedures under a real-time guidance. Once the full portfolio of products is released, the company is poised to grow even faster as their platform is aimed to solve a range of neurosurgical needs and penetrate into the OR market, where >90% of procedures take place.

ClearPoint Neuro: Becoming The Neurosurgical Platform Of Choice

ClearPoint Neuro Inc (NASDAQ: CLPT) reported Q2 revenue of $3.4 million, a 38% Y/Y increase, below the consensus estimate of $3.68 million. Functional neurosurgery navigation revenue increased 74% to $1.9 million, reflecting the resumption of elective surgical procedures.

ClearPoint Neuro Stock Dives After Q2 Earnings

ClearPoint Neuro, Inc. (CLPT) CEO Joe Burnett on Q2 2021 Results - Earnings Call Transcript

ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of -21.43% and -1.64%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Lags Revenue Estimates

Shares of ClearPoint Neuro (NASDAQ:CLPT) decreased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 54.55% year over year to ($0.17), which missed the estimate of ($0.13).

Recap: ClearPoint Neuro Q2 Earnings

Record Case Volume Supported Clinically During the Quarter Record Case Volume Supported Clinically During the Quarter

ClearPoint Neuro Reports Second Quarter 2021 Results

SOLANA BEACH, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced it has entered into a strategic and commercial partnership with German-based surgical equipment leader adeor medical AG for powered neurosurgical drill solutions.

ClearPoint Neuro, Inc. Announces Strategic and Commercial Partnership with European Surgical Equipment Leader adeor medical AG

ClearPoint Neuro is both a medical device and a biologics & drug delivery company. Both opportunities leverage a common navigation system with superior advantages over existing solutions. New product developments in the pipeline allow them to penetrate into 90% of the operating room surgeries which they are not in today.

ClearPoint Neuro: Path To Being The Neurological Navigation Platform Company

ClearPoint Neuro, Inc. (CLPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

ClearPoint Neuro, Inc. (CLPT) Stock Jumps 9.8%: Will It Continue to Soar?

AST SpaceMobile

If you are a growth investor, there is nothing more tantalizing than finding a company that could potentially grow by ten times or more in the future.

2 Stocks that could 10X in 10 years

SOLANA BEACH, Calif. and SALT LAKE CITY, July 21, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced a joint agreement with Blackrock Neurotech to develop an automated surgical solution for implanting Brain Computer Interfaces (BCIs) into patients with a wide range of neurological disorders including paralysis, ALS, blindness, hearing loss and more. This partnership will seek to leverage ClearPoint's platform and software to deliver, for the first time, a clinical solution for surgeons that is more streamlined and effective than other BCI implantation surgeries performed to date.

Blackrock Neurotech, ClearPoint Neuro to Address Neurological Disorders With Novel Brain-Computer Interface Surgical Solution

SOLANA BEACH, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, is pleased to announce that Lynnette C. Fallon has been appointed to the Company's Board of Directors effective immediately. Ms. Fallon will also become a member of the Company's Audit Committee.

News for Clearpoint Neuro Inc Stock (CLPT)